All News

The FDA has approved zenocutuzumab for the treatment of patients with NRG1 fusion-positive cholangiocarcinoma after progression on or after systemic therapy.

Data from the phase 1/2 RMC-6236-001 trial show that the RAS(ON) multiselective inhibitor daraxonrasib yielded responses in pretreated RAS-mutated PDAC.

Characterizing the heterogeneity of the CD44-SPP1 axis could help to identify therapeutic strategies for patients with advanced bladder cancer.

Ralph V. Boccia, MD, FACP, discussed the operational hurdles of administering bispecific antibodies in community settings.

Jennifer Effie Amengual, MD, discussed using epigenetic drugs to enhance immune surveillance and other novel lymphoma therapeutic strategies.

Mohamed Adam, MD, discusses switching from open to robotic Whipple procedures and the impending integration of AI-driven navigation in surgical oncology.

The FDA has set a Prescription Drug User Fee Act date of January 4, 2027, for approving taletrectinib in this ROS1-positive NSCLC population.

There are reimbursement and infrastructure challenges in oncology care, with the need for systemic changes to provide patients with life-saving behavioral interventions.

Novel bispecifics may bridge gaps in care, especially among patients in rural settings, according to Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA.

Using T-cell–redirecting therapies in less heavily pretreated populations may be a beneficial space to capitalize on, said Barry Paul, MD.

The FDA’s decision is based on data from the phase 1/2 eNRGy trial, which demonstrated that zenocutuzumab yielded responses in NRG1+ cholangiocarcinoma.

Clearance of a novel AI platform may represent an important advance in personalizing treatments for patients with early-stage breast cancer.

The ASPHO Conference brings together the world’s leading experts in pediatric oncology and hematology, and this collection of posters detail new findings in care.

ASCO has recommended expanded eligibility for independent oncology practices and stricter oversight to ensure savings benefit underserved patients.

Investigators are on track to complete the phase 1b dose-escalation portion of the RAINIER trial in 2026.

Results from the CHALLENGE trial showed that activity can reduce cancer recurrence for patients with colorectal, breast, and prostate cancers.

According to the developers, the agency’s decision could accelerate and expand the registration pathway for JNJ-1900 in head and neck cancer.

Patients who received human milk oligosaccharide demonstrated preserved Shannon Diversity index compared with control.

PSA score at 24 weeks was the strongest predictor of survival, with a PSA concentration of 0.2 ng/mL or less predicting favorable outcomes in this group.

Previous data showed deep MRD-negative responses among patients with pretreated relapsed/refractory multiple myeloma who received cevostamab.